We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Gene Therapy for Human Osteoarthritis

Magali Cucchiarini and Henning Madry
*Experimental Orthopaedics and Osteoarthritis Research,
 Saarland University Medical Center, Homburg/Saar,
 Germany*

1. Introduction

Articular cartilage has a reduced capacity for self-regeneration. Delivery of candidate genes to articular chondrocytes is an attractive strategy that has the potential to allow for a durable reestablishment of the structural integrity in osteoarthritic (OA) cartilage. Gene transfer approaches might be better suited to treat a slow and irreversible disorder such as OA over time instead of systems that are based on the application of recombinant factors with relatively short pharmacological half-lives. Current approaches that aim at re-equilibrating the metabolic balance in OA cartilage are based on the transfer of sequences coding for agents that either counteract the processes of matrix degradation or enhance the synthesis of matrix components. Importantly for the treatment of OA, the development of effective gene treatments will necessitate that the gene vehicle chosen allows for high and also sustained levels of expression of the sequence to be delivered due to the slow and irreversible progression of this disorder. The method elected to administer the therapeutic composition will be also important to achieve successful and long-term cartilage regeneration in OA patients.

2. Gene therapy

Gene therapy aims at treating human diseases via gene transfer techniques that introduce foreign genes or sequences in various cell types. The foreign material enters the cell where it is transferred towards the nucleus. Once there, it either integrates in the host genome or stays extrachromosomal under episomal forms that generally allows only for transient transgene expression. Gene transfer in sufficient number of cells is essential to allow for the production of therapeutically relevant concentrations of transgene products. The currently most employed vectors used in gene therapy trials include nonviral compounds (naked DNA, physical and chemical methods) and different viral gene carriers including adenoviral, herpes simplex virus-derived, retroviral, lentiviral, and recombinant adeno-associated viral vectors that utilize natural entry pathways in human cells (Cucchiarini et al., 2009a; Cucchiarini & Madry, 2005; Evans, 2004; Evans et al., 2004) (**Table 1**).

2.1 Nonviral vectors

Chemical methods of complexing DNA to various macromolecules include cationic lipids and liposomes, polymers, polyamines and polyethylenimines, and nanoparticles, besides the use of calcium phosphate coprecipitates. Nonviral methods avoid the risk of acquiring

replication competence inherent to viral vectors. They can be repeatedly administered, have the capacity to deliver large therapeutic genes, and are easy to produce on a large scale. Also, they do not elicit immune responses in the host organism. Still, their efficacy is often much lower than those of viral vectors. In addition, as the transgenes remain as episomes in their targets, only short-term transgene expression is achievable. To overcome these shortcomings, nonviral gene transfer strategies *in vivo* are generally based on the use of *ex vivo*-modified cells for readministration in sites of damage.

		Benefits	Shortcomings	Integration
Nonviral vectors	Liposomes, others (chemical, electrical, mechanical methods)	Noninfectious, low toxicity, easy to produce, large capacity	Relatively low efficiency, short-term transgene expression	No
Viral vectors	Adenovirus	Very high efficiency	Potential replication competence, toxicity, immunogenicity, short-term transgene expression	No
	Retrovirus	High efficiency, long-term transgene expression	Potential replication competence, risk of insertional mutagenesis	Yes
	Herpes simplex virus	High efficiency, large capacity	Relative cytotoxicity, short-term transgene expression	No
	Adeno-associated virus	Very high efficiency, long-term transgene expression	Relative difficulty to produce	No

Table 1. Gene Transfer Vectors.

2.2 Adenoviral vectors

Adenoviruses have been among the most employed systems so far. They allow for high transduction efficiencies and transgene expression in a variety of cells, allowing for direct approaches *in vivo*. Yet, there are serious concerns about their safe use in the clinics due to the development of strong host immune responses to the remaining adenoviral gene products. Another problem is the limited period of transgene expression (1-2 weeks) as the sequences delivered remain as episomes that are cleared shortly after being introduced in the cells.

2.3 Retroviral vectors

An advantage of these viruses is their ability to integrate in the host genome, allowing for the maintenance of the transgene over extended periods of time. Nevertheless, this might lead to insertional mutagenesis and a potential to activate tumorigenic sequences. Also, such vectors transduce only dividing cells with a restricted host range (and a low efficacy) and are only produce at relatively low concentrations. Therefore, *ex vivo* approaches with pre-selection of transduced cells are usually employed. Interestingly, lentiviral vectors, a subclass of retroviruses derived from the human immunodeficiency virus (HIV) that integrate in the genome of nondividing cells avoid the need for cell division and show higher levels of transduction *in vivo*. Nevertheless, there are still concerns associated with their application, including the potential for insertional mutagenesis and the psychological problem of introducing genetic material carrying HIV sequences.

2.4 Herpes simplex viral vectors (HSV)

HSV-derived vectors are large vehicles that can deliver large transgenes to almost all known cell types, including nondividing cells. Although first-generation vectors induced high levels of cytotoxicity, recent work has demonstrated that second-generation HSV were less deleterious, in particular for cartilage gene transfer. One problem remains the transient nature of transgene expression mediated by this family of vectors.

2.5 Recombinant adeno-associated viral vectors (rAAV)

Application of viral vectors raises additional safety concerns, as potentially infectious agents or sequences might be introduced *per se* in the body. This is particularly important for the treatment of OA as it is not a life-threatening disorder. In this regard, rAAV vectors based on the nonpathogenic, replication-defective human parvovirus AAV might be more adequate for gene therapy settings. rAAV are produced by complete removal of the viral gene coding sequences, making them less immunogenic than adenoviral vectors and less toxic than HSV. Also, rAAV can be transcribed in their targets at very high efficiencies for months to years due to the stabilization of the episomal transgene cassettes by concatemer formation, making them strong alternatives for direct gene transfer approaches *in vivo*. Cell division and integration are not required for expression of the foreign material delivered via rAAV, in marked contrast with retroviral vectors. Redosing of vectors is practicable with rAAV, based on the use of various serotypes of the virus. For these reasons, rAAV became a preferred gene transfer method for experimental settings *in vivo* and for clinical applications.

3. Osteoarthritis

3.1 Articular cartilage

Adult hyaline articular cartilage is an avascular and aneural tissue that does not possess a lymphatic drainage that allows for a smooth gliding of the articulating surfaces of a joint and protects the subchondral bone from mechanical stress. Hyaline articular cartilage has several laminar zones formed by chondrocytes surrounded by an intricate network of extracellular matrix rich in proteoglycans and collagen fibrils (mostly type-II collagen and also types type-VI, -IX, -XI, and -XIV collagens and additional macromolecules). Normal hyaline articular cartilage contains about 70-80% water bound to proteoglycans. The

chondrocytes regulate the structural and functional properties of the cartilage according to the applied loads by producing and degrading the extracellular matrix.

3.2 Osteoarthritis

Osteoarthritis (OA) is the most disabling condition and prevalent form of arthritis (80%). OA is a chronic disorder of diarthrodial joints, mainly characterized by a slow, progressive, and irreversible deterioration of the articular cartilage, with changes in the subchondral bone. OA also affects to a minor degree the synovial lining, ligaments, tendons, and muscles.

OA is a complex disorder characterized by the activation of inflammatory cascades and alterations of the chondrocyte phenotype, leading ultimately to cartilage breakdown (loss of the major components of the cartilage matrix). Under mechanical or biochemical stress (interleukin-1, i.e. IL-1; tumor necrosis factor alpha, i.e. TNF- α ; nitric oxide, i.e. NO, prostaglandins, matrix degradation products), the cells undergo pathological changes in gene expression patterns that impede the whole homeostasis: diminished production of matrix molecules, enhanced production of matrix-degrading enzymes (matrix metalloproteinases, i.e. MMPs; adamalysins), decreased responsiveness to reparative stimuli, degradation of the matrix, alteration of the cell viability, cell senescence with apoptosis (NO; Fas/FasL signaling).

Several nonsurgical options are available to manage the progression of OA, including pharmacological treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), slow-acting drugs in OA (SADOAs) like glucosamine, chondroitin sulfate, and diacerin, being either symptomatic slow-acting drugs in OA (SYSADOAs) or disease-modifying OA drugs (DMOADs). However, there is no convincing evidence yet that such drugs indeed modify or inhibit the progression of OA. Surgical interventions such as débridement, marrow stimulation, and osteotomy are specifically indicated in early stages of OA. Yet, restoration of a native cartilage that is identical in its structure to the normal cartilage and capable of withstanding mechanical stresses over time in OA has not been achieved to date. Causative treatment for OA therefore remains a problem, particularly troublesome for patients that are too young to undergo endoprosthetic joint replacement.

4. Osteoarthritis gene therapy

4.1 Target cells in OA – Gene transfer *in vitro*

Target cells in the OA joint include:

1. chondrocytes,
2. osteocytes,
3. cells of the synovial lining,
4. progenitor cells, or
5. cells of surrounding tissues (muscle, tendons, ligaments, meniscus).

Application of nonviral (Gerich et al., 1997b; Grossin et al., 2006; Kaul et al., 2006; Madry et al., 2004b; Madry et al., 2005; Madry et al., 2001; Nita et al., 1996; Tsuchiya et al., 2003; Zhang, H. N. et al., 2009), adenoviral (Baragi et al., 1995; Brower-Toland et al., 2001; Gelse et al., 2001; Gerich et al., 1997a; Gerich et al., 1996; Gerich et al., 1997b; Goto et al., 1999; Haupt et al., 2005; Ikeda et al., 2004; Li et al., 2004; Lou et al., 1997; Mehrara et al., 1999; Musgrave et al., 2002; Nita et al., 1996; Nixon et al., 2000; Nixon et al., 2005; Saxer et al.,

2001; Shuler et al., 2000; Smith et al., 2000; Steinert et al., 2007; Steinert et al., 2009; Steinert et al., 2008), or retroviral vectors (Baltzer et al., 1999; Gerich et al., 1997a; Gerich et al., 1996; Gerich et al., 1997b; Goto et al., 2000; Gouze, J. N. et al., 2003; Hildebrand et al., 1999; Li et al., 2004; Mason et al., 2000; Nita et al., 1996; Piera-Velazquez et al., 2002; Roessler et al., 1995; Tew et al., 2005) has been achieved in such cells with more or less success. rAAV are potent alternatives as they efficiently and durably transduce synoviocytes (Adriaansen et al., 2007; Apparailly et al., 2002; Goater et al., 2000; Goodrich et al., 2009; Hiraide et al., 2005; Traister et al., 2006; Zhang, H. G. et al., 2000), chondrocytes (Arai et al., 2000; Cucchiarini et al., 2005; Cucchiarini et al., 2009c; Cucchiarini et al., 2007; Dai & Rabie, 2007; Goodrich et al., 2009; Madry et al., 2003; Ulrich-Vinther et al., 2002; Ulrich-Vinther et al., 2005; Yokoo et al., 2005), mesenchymal stem cells (MSCs) (Chamberlain et al., 2008; Chamberlain et al., 2004; Chen, M. et al., 2011; Cucchiarini et al., 2011; Cucchiarini et al., 2005; Dai & Rabie, 2007; Ito et al., 2004; Kim, S. J. et al., 2007; Pagnotto et al., 2007; Shi & Wang, 2010; Stender et al., 2007), and other cell types relevant of the pathogenesis of OA (Arsic et al., 2004; Basile et al., 2008; Cucchiarini et al., 2009b; Gerich et al., 1997a; Gerich et al., 1997b; Ito et al., 2005; Kessler et al., 1996; Luk et al., 2003; Madry et al., 2004a; Tang et al., 2008; Wang et al., 2007; Wang et al., 2005). Regeneration of a native (structural and functional) cartilage architecture might be achieved by:

1. inhibiting inflammatory and catabolic pathways,
2. stimulating anabolic pathways to rebuild the matrix,
3. impeding cell senescence,
4. avoiding the pathological formation of osteophytes,
5. prevention of apoptosis, and/or
6. influencing several of these processes.

Inhibition of catabolic pathways has been observed when expressing inhibitors of matrix-degrading enzymes (tissue inhibitor of MMPs, i.e. TIMP) (Kafienah et al., 2003), inhibitors of proinflammatory cytokines (IL-1Ra; the soluble receptors sIL-1R or sTNFR) (Attur et al., 2002; Baragi et al., 1995; Gouze, J. N. et al., 2003; Haupt et al., 2005; Roessler et al., 1995; Zhang, H. G. et al., 2000; Zhang, X. et al., 2006), and chondroprotective cytokines (IL-4; IL-10) (Kim, S. H. et al., 2001; Zhang, X. et al., 2006). Activation of anabolic processes has been noted by single or combined administration of components of the cartilage matrix or of the enzymes that synthesize them (Dharmavaram et al., 1999; Venkatesan et al., 2004), of growth factors and receptors (insulin-like growth factor I, i.e. IGF-I; fibroblast growth factor 2, i.e. FGF-2; bone morphogenetic proteins, i.e. BMPs; transforming growth factor beta, i.e. TGF- β) (Brower-Toland et al., 2001; Chen, B. et al., 2010; Cucchiarini et al., 2011; Cucchiarini et al., 2005; Cucchiarini et al., 2009c; Haupt et al., 2005; Lee et al., 2005; Madry et al., 2004b; Madry et al., 2001; Nixon et al., 2000; Nixon et al., 2005; Saxer et al., 2001; Schmal et al., 2005; Shuler et al., 2000; Smith et al., 2000; Ulrich-Vinther et al., 2005), and of transcription factors (SOX family of DNA-binding proteins, i.e. SOX5, SOX6, SOX9) (Cucchiarini et al., 2007; Ikeda et al., 2004; Li et al., 2004; Tew et al., 2005; Tsuchiya et al., 2003). Restoration of cell vitality and activation of proliferation have been achieved by application of IGF-I or FGF-2 (Cucchiarini et al., 2011; Cucchiarini et al., 2005; Cucchiarini et al., 2009c; Kaul et al., 2006; Madry et al., 2004b; Madry et al., 2001; Schmal et al., 2005), telomerase (hTERT) (Piera-Velazquez et al., 2002), of inhibitors of apoptosis (bcl-2) (Surendran et al., 2006), or of the heat shock protein 70 (HSP70) (Grossin et al., 2006). Remarkably, approaches that influence several of these

processes have been also successfully attempted, like combining the transfer of inhibitors of catabolism pathways and of activators of anabolic events (IGF-I/IL-1Ra) (Haupt et al., 2005; Nixon et al., 2005), as well as that of activators of anabolic and proliferative processes (FGF-2/SOX9 or FGF-2/IGF-I) (Cucchiaroni et al., 2009c; Orth et al., 2011).

4.2 Gene transfer *in vivo*

4.2.1 Direct gene transfer

The key issue in establishing an efficient therapy against OA is to access the targets of the treatment when the cells reside in the joint cavity. The following approaches have been therefore developed:

1. systemic delivery and
2. intraarticular administration:
 - 2.1 by injection or
 - 2.2 using arthrotomy

Systemic approaches are better suited to target diseases that are systemic in nature like rheumatoid arthritis (RA) (Evans et al., 2006b, 2009; Jorgensen & Apparailly, 2010).

Local administration of components might be preferable for OA that affects only a limited number of joints without major systemic manifestations. Intraarticular injection of most vector types preferentially transduce the synovium (Ghivizzani et al., 1997; Gouze, E. et al., 2002; Nita et al., 1996; Roessler et al., 1993), being rather suited for strategies aiming at inhibiting inflammatory and catabolic pathways (and a common approach employed against experimental RA). Direct application of gene vectors has been attempted in experimental OA using sequences coding for IL-1Ra (Fernandes et al., 1999; Frisbie et al., 2002; Frisbie & McIlwraith, 2000; Zhang, X. et al., 2006), IL-10 (Zhang, X. et al., 2006), HSP70 (Grossin et al., 2006), gene silencers (Chen, L. X. et al., 2008), or kallistatin and thrombospondin-1 (Hsieh et al., 2009; Hsieh et al., 2010). Yet, even if cartilage breakdown is contained, this may not be sufficient to fully compensate for the loss of matrix elements and cells noted during the disease progression. In this regard, synthesis of cartilage matrix components might be stimulated by providing vectors carrying genes for anabolic factors (FGF-2, IGF-I) (Chen, B. et al., 2010).

4.2.2 Indirect gene transfer

Ex vivo gene therapy is more complex but safer as no free vector particles are introduced in the body. Also, modified cells can be controlled, tested, and selected in culture. Administration of cells is also a means to increase the cellularity like needed for cases of severe OA.

Synoviocytes have been mostly employed to deliver inhibitors of inflammatory and catabolic processes (Pelletier et al., 1997; Zhang, X. et al., 2004). Such pathways were regulated by injecting cells overexpressing an IL-1Ra alone (Pelletier et al., 1997; Zhang, X. et al., 2004) or with IL-10 (Zhang, X. et al., 2004). Again, although OA was reduced in association with decreased cartilage breakdown, complete resurfacing was not reported. Nevertheless, the use of differentiated cells is impaired by the invasive methods of preparation from unaffected sites with a limited supply and by common changes in cell phenotype observed upon passaging in culture. Also, implantation of committed cells generally leads to the formation of a poorly differentiated (fibrous) cartilage. Progenitor cells might be better suited to generate a cartilage of enhanced quality in transplantation settings.

They can be easily isolated from multiple tissues (bone marrow, periosteum, perichondrium, muscle, fat, subdermis, cartilage, bone, synovial membrane, ligaments), even in OA patients, maintaining a multilineage potential with a reliability for differentiation and a capacity for expansion (Barry & Murphy, 2004; Yoo et al., 2000). Remarkably, injection of muscle-derived stem cells modified by combined gene transfer of BMP-4 with sFlt1 (an antagonist of the vascular endothelial growth factor, i.e. VEGF) allowed for cartilage repair in a rat model of OA (Matsumoto et al., 2009).

5. Clinical trials

Preclinical data, as those described above, have encouraged the initiation of human clinical trials mostly for RA. The first studies were based on retroviral gene transfer of human IL-1Ra in synoviocytes from RA patients and reinjection in the metacarpophalangeal joint (Evans et al., 2000a; Evans et al., 1996; Wehling et al., 2009). Transgene expression was noted locally without adverse events, leading to clinical improvements in some patients, encouraging the implementation of phase II studies (Evans, 2005; Evans et al., 2005a; Evans et al., 2000b; Evans et al., 2006a, 2008; Evans et al., 2004; Evans et al., 2005b; Robbins et al., 2003). Direct intraarticular injection of rAAV carrying an sTNFR-immunoglobulin in RA patients revealed that the treatment was safe and well tolerated (Evans, 2005; Evans et al., 2005a; Evans et al., 2006a, 2008; Mease et al., 2009), and a phase I/II trial was subsequently started. Regarding OA, a phase I protocol is ongoing, based on an *ex vivo* approach using the retroviral transfer of TGF- β (Evans et al., 2008).

6. Conclusions

Gene therapy holds great promise, but issues that need to be addressed include the duration of transgene expression, extended analyses in clinically relevant animal models, the benefit of *ex vivo* genetically modified cells versus direct approaches, and the identification of optimal therapeutic factors. Future studies will also have to shed light on the safety of these approaches regarding the nonlethal nature of OA. Successful application of gene therapy for OA requires a combined effort of surgeons and basic scientists in order to improve the currently available gene transfer systems.

7. Acknowledgments and funding

This work was supported by grants of the *Deutsche Forschungsgemeinschaft* (DFG CU 55/1-1, 1-2, 1-3) and of the *Deutsche Arthrose-Hilfe*.

8. Declaration of conflicting interests

The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.

9. References

Adriaansen, J., Khoury, M., de Cortie, C. J., Fallaux, F. J., Bigey, P., Scherman, D., Gould, D. J., Chernajovsky, Y., Apparailly, F., Jorgensen, C., Vervoordeldonk, M. J. & Tak, P. P.

- (2007). Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. *Ann Rheum Dis*, Vol. 66, No. 9, (Sep) pp. 1143-50, 0003-4967 (Print) 0003-4967 (Linking)
- Apparailly, F., Millet, V., Noel, D., Jacquet, C., Sany, J. & Jorgensen, C. (2002). Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. *Hum Gene Ther*, Vol. 13, No. 10, (Jul 1) pp. 1179-88, 1043-0342 (Print) 1043-0342 (Linking)
- Arai, Y., Kubo, T., Fushiki, S., Mazda, O., Nakai, H., Iwaki, Y., Imanishi, J. & Hirasawa, Y. (2000). Gene delivery to human chondrocytes by an adeno associated virus vector. *J Rheumatol*, Vol. 27, No. 4, (Apr) pp. 979-82, 0315-162X (Print) 0315-162X (Linking)
- Arsic, N., Zacchigna, S., Zentilin, L., Ramirez-Correa, G., Pattarini, L., Salvi, A., Sinagra, G. & Giacca, M. (2004). Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. *Mol Ther*, Vol. 10, No. 5, (Nov) pp. 844-54, 1525-0016 (Print) 1525-0016 (Linking)
- Attur, M. G., Dave, M. N., Leung, M. Y., Cipolletta, C., Meseck, M., Woo, S. L. & Amin, A. R. (2002). Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. *J Immunol*, Vol. 168, No. 4, (Feb 15) pp. 2001-10, 0022-1767 (Print) 0022-1767 (Linking)
- Baltzer, A. W., Whalen, J. D., Muzzonegro, T., Georgescu, H. I., Robbins, P. D. & Evans, C. H. (1999). [In vitro transduction of human osteoblast cell populations with retroviral vectors]. *Z Rheumatol*, Vol. 58, No. 2, (Apr) pp. 88-94, 0340-1855 (Print) 0340-1855 (Linking)
- Baragi, V. M., Renkiewicz, R. R., Jordan, H., Bonadio, J., Hartman, J. W. & Roessler, B. J. (1995). Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation. *J Clin Invest*, Vol. 96, No. 5, (Nov) pp. 2454-60, 0021-9738 (Print) 0021-9738 (Linking)
- Barry, F. P. & Murphy, J. M. (2004). Mesenchymal stem cells: clinical applications and biological characterization. *Int J Biochem Cell Biol*, Vol. 36, No. 4, (Apr) pp. 568-84, 1357-2725 (Print) 1357-2725 (Linking)
- Basile, P., Dadali, T., Jacobson, J., Hasslund, S., Ulrich-Vinther, M., Soballe, K., Nishio, Y., Drissi, M. H., Langstein, H. N., Mitten, D. J., O'Keefe, R. J., Schwarz, E. M. & Awad, H. A. (2008). Freeze-dried tendon allografts as tissue-engineering scaffolds for Gdf5 gene delivery. *Mol Ther*, Vol. 16, No. 3, (Mar) pp. 466-73, 1525-0024 (Electronic) 1525-0016 (Linking)
- Brower-Toland, B. D., Saxer, R. A., Goodrich, L. R., Mi, Z., Robbins, P. D., Evans, C. H. & Nixon, A. J. (2001). Direct adenovirus-mediated insulin-like growth factor I gene transfer enhances transplant chondrocyte function. *Hum Gene Ther*, Vol. 12, No. 2, (Jan 20) pp. 117-29, 1043-0342 (Print) 1043-0342 (Linking)
- Chamberlain, J. R., Deyle, D. R., Schwarze, U., Wang, P., Hirata, R. K., Li, Y., Byers, P. H. & Russell, D. W. (2008). Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. *Mol Ther*, Vol. 16, No. 1, (Jan) pp. 187-93, 1525-0024 (Electronic) 1525-0016 (Linking)
- Chamberlain, J. R., Schwarze, U., Wang, P. R., Hirata, R. K., Hankenson, K. D., Pace, J. M., Underwood, R. A., Song, K. M., Sussman, M., Byers, P. H. & Russell, D. W. (2004). Gene targeting in stem cells from individuals with osteogenesis imperfecta. *Science*, Vol. 303, No. 5661, (Feb 20) pp. 1198-201, 1095-9203 (Electronic) 0036-8075 (Linking)

- Chen, B., Qin, J., Wang, H., Magdalou, J. & Chen, L. (2010). Effects of adenovirus-mediated bFGF, IL-1Ra and IGF-1 gene transfer on human osteoarthritic chondrocytes and osteoarthritis in rabbits. *Exp Mol Med*, Vol. 42, No. 10, (Oct 31) pp. 684-95, 1226-3613 (Print) 1226-3613 (Linking)
- Chen, L. X., Lin, L., Wang, H. J., Wei, X. L., Fu, X., Zhang, J. Y. & Yu, C. L. (2008). Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. *Osteoarthritis Cartilage*, Vol. 16, No. 2, (Feb) pp. 174-84, 1063-4584 (Print) 1063-4584 (Linking)
- Chen, M., Song, K., Rao, N., Huang, M., Huang, Z. & Cao, Y. (2011). Roles of exogenously regulated bFGF expression in angiogenesis and bone regeneration in rat calvarial defects. *Int J Mol Med*, Vol. 27, No. 4, (Apr) pp. 545-53, 1791-244X (Electronic) 1107-3756 (Linking)
- Cucchiari, M., Ekici, M., Schetting, S., Kohn, D. & Madry, H. (2011). Metabolic activities and chondrogenic differentiation of human mesenchymal stem cells following recombinant adeno-associated virus-mediated gene transfer and overexpression of fibroblast growth factor 2. *Tissue Eng Part A*, Vol. No. 17, (Aug) pp. 1921-33
- Cucchiari, M., Heiligenstein, S., Kohn, D. & Madry, H. (2009a). [Molecular tools to remodel osteoarthritic articular cartilage : growth, transcription, and signaling factors]. *Orthopade*, Vol. 38, No. 11, (Nov) pp. 1063-70, 1433-0431 (Electronic) 0085-4530 (Linking)
- Cucchiari, M. & Madry, H. (2005). Gene therapy for cartilage defects. *J Gene Med*, Vol. 7, No. 12, (Dec) pp. 1495-509, 1099-498X (Print) 1099-498X (Linking)
- Cucchiari, M., Madry, H., Ma, C., Thurn, T., Zurakowski, D., Menger, M. D., Kohn, D., Trippel, S. B. & Terwilliger, E. F. (2005). Improved tissue repair in articular cartilage defects in vivo by rAAV-mediated overexpression of human fibroblast growth factor 2. *Mol Ther*, Vol. 12, No. 2, (Aug) pp. 229-38, 1525-0016 (Print) 1525-0016 (Linking)
- Cucchiari, M., Schetting, S., Terwilliger, E. F., Kohn, D. & Madry, H. (2009b). rAAV-mediated overexpression of FGF-2 promotes cell proliferation, survival, and alpha-SMA expression in human meniscal lesions. *Gene Ther*, Vol. 16, No. 11, (Nov) pp. 1363-72, 1476-5462 (Electronic) 0969-7128 (Linking)
- Cucchiari, M., Terwilliger, E. F., Kohn, D. & Madry, H. (2009c). Remodelling of human osteoarthritic cartilage by FGF-2, alone or combined with Sox9 via rAAV gene transfer. *J Cell Mol Med*, Vol. 13, No. 8B, (Aug) pp. 2476-88, 1582-4934 (Electronic) 1582-1838 (Linking)
- Cucchiari, M., Thurn, T., Weimer, A., Kohn, D., Terwilliger, E. F. & Madry, H. (2007). Restoration of the extracellular matrix in human osteoarthritic articular cartilage by overexpression of the transcription factor SOX9. *Arthritis Rheum*, Vol. 56, No. 1, (Jan) pp. 158-67, 0004-3591 (Print) 0004-3591 (Linking)
- Dai, J. & Rabie, A. B. (2007). Recombinant adeno-associated virus vector hybrids efficiently target different skeletal cells. *Front Biosci*, Vol. 12, No. pp. 4280-7, 1093-4715 (Electronic) 1093-4715 (Linking)
- Dharmavaram, R. M., Liu, G., Tuan, R. S., Stokes, D. G. & Jimenez, S. A. (1999). Stable transfection of human fetal chondrocytes with a type II procollagen minigene: expression of the mutant protein and alterations in the structure of the extracellular

- matrix in vitro. *Arthritis Rheum*, Vol. 42, No. 7, (Jul) pp. 1433-42, 0004-3591 (Print) 0004-3591 (Linking)
- Evans, C. H. (2004). Gene therapies for osteoarthritis. *Curr Rheumatol Rep*, Vol. 6, No. 1, (Feb) pp. 31-40, 1523-3774 (Print) 1523-3774 (Linking)
- Evans, C. H. (2005). Gene therapy: what have we accomplished and where do we go from here? *J Rheumatol Suppl*, Vol. 72, No. (Jan) pp. 17-20, 0380-0903 (Print) 0380-0903 (Linking)
- Evans, C. H., Ghivizzani, S. C., Herndon, J. H. & Robbins, P. D. (2005a). Gene therapy for the treatment of musculoskeletal diseases. *J Am Acad Orthop Surg*, Vol. 13, No. 4, (Jul-Aug) pp. 230-42, 1067-151X (Print) 1067-151X (Linking)
- Evans, C. H., Ghivizzani, S. C., Herndon, J. H., Wasko, M. C., Reinecke, J., Wehling, P. & Robbins, P. D. (2000a). Clinical trials in the gene therapy of arthritis. *Clin Orthop Relat Res*, Vol. No. 379 Suppl, (Oct) pp. S300-7, 0009-921X (Print) 0009-921X (Linking)
- Evans, C. H., Ghivizzani, S. C., Oligino, T. J. & Robbins, P. D. (2000b). Gene therapy for autoimmune disorders. *J Clin Immunol*, Vol. 20, No. 5, (Sep) pp. 334-46, 0271-9142 (Print) 0271-9142 (Linking)
- Evans, C. H., Ghivizzani, S. C. & Robbins, P. D. (2006a). Gene therapy for arthritis: what next? *Arthritis Rheum*, Vol. 54, No. 6, (Jun) pp. 1714-29, 0004-3591 (Print) 0004-3591 (Linking)
- Evans, C. H., Ghivizzani, S. C. & Robbins, P. D. (2006b). Will arthritis gene therapy become a clinical reality? *Nat Clin Pract Rheumatol*, Vol. 2, No. 7, (Jul) pp. 344-5, 1745-8382 (Print) 1745-8382 (Linking)
- Evans, C. H., Ghivizzani, S. C. & Robbins, P. D. (2008). Arthritis gene therapy's first death. *Arthritis Res Ther*, Vol. 10, No. 3, pp. 110, 1478-6362 (Electronic) 1478-6354 (Linking)
- Evans, C. H., Ghivizzani, S. C. & Robbins, P. D. (2009). Gene therapy of the rheumatic diseases: 1998 to 2008. *Arthritis Res Ther*, Vol. 11, No. 1, pp. 209, 1478-6362 (Electronic) 1478-6354 (Linking)
- Evans, C. H., Gouze, J. N., Gouze, E., Robbins, P. D. & Ghivizzani, S. C. (2004). Osteoarthritis gene therapy. *Gene Ther*, Vol. 11, No. 4, (Feb) pp. 379-89, 0969-7128 (Print) 0969-7128 (Linking)
- Evans, C. H., Robbins, P. D., Ghivizzani, S. C., Herndon, J. H., Kang, R., Bahnson, A. B., Barranger, J. A., Elders, E. M., Gay, S., Tomaino, M. M., Wasko, M. C., Watkins, S. C., Whiteside, T. L., Glorioso, J. C., Lotze, M. T. & Wright, T. M. (1996). Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. *Hum Gene Ther*, Vol. 7, No. 10, (Jun 20) pp. 1261-80, 1043-0342 (Print) 1043-0342 (Linking)
- Evans, C. H., Robbins, P. D., Ghivizzani, S. C., Wasko, M. C., Tomaino, M. M., Kang, R., Muzzonigro, T. A., Vogt, M., Elder, E. M., Whiteside, T. L., Watkins, S. C. & Herndon, J. H. (2005b). Gene transfer to human joints: progress toward a gene therapy of arthritis. *Proc Natl Acad Sci U S A*, Vol. 102, No. 24, (Jun 14) pp. 8698-703, 0027-8424 (Print) 0027-8424 (Linking)
- Fernandes, J., Tardif, G., Martel-Pelletier, J., Lascau-Coman, V., Dupuis, M., Moldovan, F., Sheppard, M., Krishnan, B. R. & Pelletier, J. P. (1999). In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of

- osteoarthritis progression. *Am J Pathol*, Vol. 154, No. 4, (Apr) pp. 1159-69, 0002-9440 (Print) 0002-9440 (Linking)
- Frisbie, D. D., Ghivizzani, S. C., Robbins, P. D., Evans, C. H. & McIlwraith, C. W. (2002). Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. *Gene Ther*, Vol. 9, No. 1, (Jan) pp. 12-20, 0969-7128 (Print) 0969-7128 (Linking)
- Frisbie, D. D. & McIlwraith, C. W. (2000). Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis. *Clin Orthop Relat Res*, Vol. No. 379 Suppl, (Oct) pp. S273-87, 0009-921X (Print) 0009-921X (Linking)
- Gelse, K., Jiang, Q. J., Aigner, T., Ritter, T., Wagner, K., Poschl, E., von der Mark, K. & Schneider, H. (2001). Fibroblast-mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer. *Arthritis Rheum*, Vol. 44, No. 8, (Aug) pp. 1943-53, 0004-3591 (Print) 0004-3591 (Linking)
- Gerich, T. G., Ghivizzani, S., Fu, F. H., Robbins, P. D. & Evans, C. H. (1997a). [Gene transfer into the patellar tendon of rabbits: a preliminary study of locoregional expression of growth factors]. *Wien Klin Wochenschr*, Vol. 109, No. 11, (Jun 6) pp. 384-9, 0043-5325 (Print) 0043-5325 (Linking)
- Gerich, T. G., Kang, R., Fu, F. H., Robbins, P. D. & Evans, C. H. (1996). Gene transfer to the rabbit patellar tendon: potential for genetic enhancement of tendon and ligament healing. *Gene Ther*, Vol. 3, No. 12, (Dec) pp. 1089-93, 0969-7128 (Print) 0969-7128 (Linking)
- Gerich, T. G., Lobenhoffer, H. P., Fu, F. H., Robbins, P. D. & Evans, C. H. (1997b). [Virally mediated gene transfer in the patellar tendon. An experimental study in rabbits]. *Unfallchirurg*, Vol. 100, No. 5, (May) pp. 354-62, 0177-5537 (Print) 0177-5537 (Linking)
- Ghivizzani, S. C., Lechman, E. R., Tio, C., Mule, K. M., Chada, S., McCormack, J. E., Evans, C. H. & Robbins, P. D. (1997). Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy. *Gene Ther*, Vol. 4, No. 9, (Sep) pp. 977-82, 0969-7128 (Print) 0969-7128 (Linking)
- Goater, J., Muller, R., Kollias, G., Firestein, G. S., Sanz, I., O'Keefe, R. J. & Schwarz, E. M. (2000). Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. *J Rheumatol*, Vol. 27, No. 4, (Apr) pp. 983-9, 0315-162X (Print) 0315-162X (Linking)
- Goodrich, L. R., Choi, V. W., Carbone, B. A., McIlwraith, C. W. & Samulski, R. J. (2009). Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors. *Hum Gene Ther*, Vol. 20, No. 12, (Dec) pp. 1697-702, 1557-7422 (Electronic) 1043-0342 (Linking)
- Goto, H., Shuler, F. D., Lamsam, C., Moller, H. D., Niyibizi, C., Fu, F. H., Robbins, P. D. & Evans, C. H. (1999). Transfer of lacZ marker gene to the meniscus. *J Bone Joint Surg Am*, Vol. 81, No. 7, (Jul) pp. 918-25, 0021-9355 (Print)
- Goto, H., Shuler, F. D., Niyibizi, C., Fu, F. H., Robbins, P. D. & Evans, C. H. (2000). Gene therapy for meniscal injury: enhanced synthesis of proteoglycan and collagen by meniscal cells transduced with a TGFbeta(1) gene. *Osteoarthritis Cartilage*, Vol. 8, No. 4, (Jul) pp. 266-71, 1063-4584 (Print) 1063-4584 (Linking)

- Gouze, E., Pawliuk, R., Pilapil, C., Gouze, J. N., Fleet, C., Palmer, G. D., Evans, C. H., Leboulch, P. & Ghivizzani, S. C. (2002). In vivo gene delivery to synovium by lentiviral vectors. *Mol Ther*, Vol. 5, No. 4, (Apr) pp. 397-404, 1525-0016 (Print) 1525-0016 (Linking)
- Gouze, J. N., Gouze, E., Palmer, G. D., Liew, V. S., Pascher, A., Betz, O. B., Thornhill, T. S., Evans, C. H., Grodzinsky, A. J. & Ghivizzani, S. C. (2003). A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer. *Arthritis Res Ther*, Vol. 5, No. 5, pp. R301-9, 1478-6362 (Electronic) 1478-6354 (Linking)
- Grossin, L., Cournil-Henrionnet, C., Pinzano, A., Gaborit, N., Dumas, D., Etienne, S., Stoltz, J. F., Terlain, B., Netter, P., Mir, L. M. & Gillet, P. (2006). Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis. *FASEB J*, Vol. 20, No. 1, (Jan) pp. 65-75, 1530-6860 (Electronic) 0892-6638 (Linking)
- Haupt, J. L., Frisbie, D. D., McIlwraith, C. W., Robbins, P. D., Ghivizzani, S., Evans, C. H. & Nixon, A. J. (2005). Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. *J Orthop Res*, Vol. 23, No. 1, (Jan) pp. 118-26, 0736-0266 (Print) 0736-0266 (Linking)
- Hildebrand, K. A., Deie, M., Allen, C. R., Smith, D. W., Georgescu, H. I., Evans, C. H., Robbins, P. D. & Woo, S. L. (1999). Early expression of marker genes in the rabbit medial collateral and anterior cruciate ligaments: the use of different viral vectors and the effects of injury. *J Orthop Res*, Vol. 17, No. 1, (Jan) pp. 37-42, 0736-0266 (Print) 0736-0266 (Linking)
- Hiraide, A., Yokoo, N., Xin, K. Q., Okuda, K., Mizukami, H., Ozawa, K. & Saito, T. (2005). Repair of articular cartilage defect by intraarticular administration of basic fibroblast growth factor gene, using adeno-associated virus vector. *Hum Gene Ther*, Vol. 16, No. 12, (Dec) pp. 1413-21, 1043-0342 (Print) 1043-0342 (Linking)
- Hsieh, J. L., Shen, P. C., Shiau, A. L., Jou, I. M., Lee, C. H., Teo, M. L., Wang, C. R., Chao, J., Chao, L. & Wu, C. L. (2009). Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. *Hum Gene Ther*, Vol. 20, No. 2, (Feb) pp. 147-58, 1557-7422 (Electronic) 1043-0342 (Linking)
- Hsieh, J. L., Shen, P. C., Shiau, A. L., Jou, I. M., Lee, C. H., Wang, C. R., Teo, M. L. & Wu, C. L. (2010). Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis. *J Orthop Res*, Vol. 28, No. 10, (Oct) pp. 1300-6, 1554-527X (Electronic) 0736-0266 (Linking)
- Ikeda, T., Kamekura, S., Mabuchi, A., Kou, I., Seki, S., Takato, T., Nakamura, K., Kawaguchi, H., Ikegawa, S. & Chung, U. I. (2004). The combination of SOX5, SOX6, and SOX9 (the SOX trio) provides signals sufficient for induction of permanent cartilage. *Arthritis Rheum*, Vol. 50, No. 11, (Nov) pp. 3561-73, 0004-3591 (Print) 0004-3591 (Linking)
- Ito, H., Goater, J. J., Tiyyapatanaputi, P., Rubery, P. T., O'Keefe, R. J. & Schwarz, E. M. (2004). Light-activated gene transduction of recombinant adeno-associated virus in human mesenchymal stem cells. *Gene Ther*, Vol. 11, No. 1, (Jan) pp. 34-41, 0969-7128 (Print) 0969-7128 (Linking)

- Ito, H., Koefoed, M., Tiyyapattanaputi, P., Gromov, K., Goater, J. J., Carmouche, J., Zhang, X., Rubery, P. T., Rabinowitz, J., Samulski, R. J., Nakamura, T., Soballe, K., O'Keefe, R. J., Boyce, B. F. & Schwarz, E. M. (2005). Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. *Nat Med*, Vol. 11, No. 3, (Mar) pp. 291-7, 1078-8956 (Print) 1078-8956 (Linking)
- Jorgensen, C. & Apparailly, F. (2010). Prospects for gene therapy in inflammatory arthritis. *Best Pract Res Clin Rheumatol*, Vol. 24, No. 4, (Aug) pp. 541-52, 1532-1770 (Electronic) 1521-6942 (Linking)
- Kafienah, W., Al-Fayez, F., Hollander, A. P. & Barker, M. D. (2003). Inhibition of cartilage degradation: a combined tissue engineering and gene therapy approach. *Arthritis Rheum*, Vol. 48, No. 3, (Mar) pp. 709-18, 0004-3591 (Print) 0004-3591 (Linking)
- Kaul, G., Cucchiari, M., Arntzen, D., Zurakowski, D., Menger, M. D., Kohn, D., Trippel, S. B. & Madry, H. (2006). Local stimulation of articular cartilage repair by transplantation of encapsulated chondrocytes overexpressing human fibroblast growth factor 2 (FGF-2) in vivo. *J Gene Med*, Vol. 8, No. 1, (Jan) pp. 100-11, 1099-498X (Print) 1099-498X (Linking)
- Kessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J. & Byrne, B. J. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. *Proc Natl Acad Sci U S A*, Vol. 93, No. 24, (Nov 26) pp. 14082-7, 0027-8424 (Print) 0027-8424 (Linking)
- Kim, S. H., Kim, S., Evans, C. H., Ghivizzani, S. C., Oligino, T. & Robbins, P. D. (2001). Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. *J Immunol*, Vol. 166, No. 5, (Mar 1) pp. 3499-505, 0022-1767 (Print) 0022-1767 (Linking)
- Kim, S. J., Lee, W. I., Heo, H., Shin, O., Kwon, Y. K. & Lee, H. (2007). Stable gene expression by self-complementary adeno-associated viruses in human MSCs. *Biochem Biophys Res Commun*, Vol. 360, No. 3, (Aug 31) pp. 573-9, 0006-291X (Print) 0006-291X (Linking)
- Lee, D. K., Choi, K. B., Oh, I. S., Song, S. U., Hwang, S., Lim, C. L., Hyun, J. P., Lee, H. Y., Chi, G. F., Yi, Y., Yip, V., Kim, J., Lee, E. B., Noh, M. J. & Lee, K. H. (2005). Continuous transforming growth factor beta1 secretion by cell-mediated gene therapy maintains chondrocyte redifferentiation. *Tissue Eng*, Vol. 11, No. 1-2, (Jan-Feb) pp. 310-8, 1076-3279 (Print) 1076-3279 (Linking)
- Li, Y., Tew, S. R., Russell, A. M., Gonzalez, K. R., Hardingham, T. E. & Hawkins, R. E. (2004). Transduction of passaged human articular chondrocytes with adenoviral, retroviral, and lentiviral vectors and the effects of enhanced expression of SOX9. *Tissue Eng*, Vol. 10, No. 3-4, (Mar-Apr) pp. 575-84, 1076-3279 (Print) 1076-3279 (Linking)
- Lou, J., Kubota, H., Hotokezaka, S., Ludwig, F. J. & Manske, P. R. (1997). In vivo gene transfer and overexpression of focal adhesion kinase (pp125 FAK) mediated by recombinant adenovirus-induced tendon adhesion formation and epitenon cell change. *J Orthop Res*, Vol. 15, No. 6, (Nov) pp. 911-8, 0736-0266 (Print) 0736-0266 (Linking)
- Luk, K. D., Chen, Y., Cheung, K. M., Kung, H. F., Lu, W. W. & Leong, J. C. (2003). Adeno-associated virus-mediated bone morphogenetic protein-4 gene therapy for in vivo

- bone formation. *Biochem Biophys Res Commun*, Vol. 308, No. 3, (Aug 29) pp. 636-45, 0006-291X (Print) 0006-291X (Linking)
- Madry, H., Cucchiari, M., Kaul, G., Kohn, D., Terwilliger, E. F. & Trippel, S. B. (2004a). Menisci are efficiently transduced by recombinant adeno-associated virus vectors in vitro and in vivo. *Am J Sports Med*, Vol. 32, No. 8, (Dec) pp. 1860-5, 0363-5465 (Print) 0363-5465 (Linking)
- Madry, H., Cucchiari, M., Terwilliger, E. F. & Trippel, S. B. (2003). Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage. *Hum Gene Ther*, Vol. 14, No. 4, (Mar 1) pp. 393-402, 1043-0342 (Print) 1043-0342 (Linking)
- Madry, H., Emkey, G., Zurakowski, D. & Trippel, S. B. (2004b). Overexpression of human fibroblast growth factor 2 stimulates cell proliferation in an ex vivo model of articular chondrocyte transplantation. *J Gene Med*, Vol. 6, No. 2, (Feb) pp. 238-45, 1099-498X (Print) 1099-498X (Linking)
- Madry, H., Kaul, G., Cucchiari, M., Stein, U., Zurakowski, D., Remberger, K., Menger, M. D., Kohn, D. & Trippel, S. B. (2005). Enhanced repair of articular cartilage defects in vivo by transplanted chondrocytes overexpressing insulin-like growth factor I (IGF-I). *Gene Ther*, Vol. 12, No. 15, (Aug) pp. 1171-9, 0969-7128 (Print) 0969-7128 (Linking)
- Madry, H., Zurakowski, D. & Trippel, S. B. (2001). Overexpression of human insulin-like growth factor-I promotes new tissue formation in an ex vivo model of articular chondrocyte transplantation. *Gene Ther*, Vol. 8, No. 19, (Oct) pp. 1443-9, 0969-7128 (Print) 0969-7128 (Linking)
- Mason, J. M., Breitbart, A. S., Barcia, M., Porti, D., Pergolizzi, R. G. & Grande, D. A. (2000). Cartilage and bone regeneration using gene-enhanced tissue engineering. *Clin Orthop Relat Res*, Vol. No. 379 Suppl, (Oct) pp. S171-8, 0009-921X (Print) 0009-921X (Linking)
- Matsumoto, T., Cooper, G. M., Gharaibeh, B., Meszaros, L. B., Li, G., Usas, A., Fu, F. H. & Huard, J. (2009). Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle-derived stem cells expressing bone morphogenetic protein 4 and soluble Flt-1. *Arthritis Rheum*, Vol. 60, No. 5, (May) pp. 1390-405, 0004-3591 (Print) 0004-3591 (Linking)
- Mease, P. J., Hobbs, K., Chalmers, A., El-Gabalawy, H., Bookman, A., Keystone, E., Furst, D. E., Anklesaria, P. & Heald, A. E. (2009). Local delivery of a recombinant adeno-associated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. *Ann Rheum Dis*, Vol. 68, No. 8, (Aug) pp. 1247-54, 1468-2060 (Electronic) 0003-4967 (Linking)
- Mehrara, B. J., Saadeh, P. B., Steinbrech, D. S., Dudziak, M., Spector, J. A., Greenwald, J. A., Gittes, G. K. & Longaker, M. T. (1999). Adenovirus-mediated gene therapy of osteoblasts in vitro and in vivo. *J Bone Miner Res*, Vol. 14, No. 8, (Aug) pp. 1290-301, 0884-0431 (Print) 0884-0431 (Linking)
- Musgrave, D. S., Pruchnic, R., Bosch, P., Ziran, B. H., Whalen, J. & Huard, J. (2002). Human skeletal muscle cells in ex vivo gene therapy to deliver bone morphogenetic protein-2. *J Bone Joint Surg Br*, Vol. 84, No. 1, (Jan) pp. 120-7, 0301-620X (Print)

- Nita, I., Ghivizzani, S. C., Galea-Lauri, J., Bandara, G., Georgescu, H. I., Robbins, P. D.&Evans, C. H. (1996). Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo. *Arthritis Rheum*, Vol. 39, No. 5, (May) pp. 820-8, 0004-3591 (Print) 0004-3591 (Linking)
- Nixon, A. J., Brower-Toland, B. D., Bent, S. J., Saxer, R. A., Wilke, M. J., Robbins, P. D.&Evans, C. H. (2000). Insulinlike growth factor-I gene therapy applications for cartilage repair. *Clin Orthop Relat Res*, Vol. No. 379 Suppl, (Oct) pp. S201-13, 0009-921X (Print) 0009-921X (Linking)
- Nixon, A. J., Haupt, J. L., Frisbie, D. D., Morisset, S. S., McIlwraith, C. W., Robbins, P. D., Evans, C. H.&Ghivizzani, S. (2005). Gene-mediated restoration of cartilage matrix by combination insulin-like growth factor-I/interleukin-1 receptor antagonist therapy. *Gene Ther*, Vol. 12, No. 2, (Jan) pp. 177-86, 0969-7128 (Print) 0969-7128 (Linking)
- Orth, P., Kaul, G., Cucchiaroni, M., Zurakowski, D., Menger, M. D., Kohn, D.&Madry, H. (2011). Transplanted articular chondrocytes co-overexpressing IGF-I and FGF-2 stimulate cartilage repair in vivo. *Knee Surg Sports Traumatol Arthrosc*, Vol. No. (Feb 25) pp. 1433-7347 (Electronic) 0942-2056 (Linking)
- Pagnotto, M. R., Wang, Z., Karpie, J. C., Ferretti, M., Xiao, X.&Chu, C. R. (2007). Adeno-associated viral gene transfer of transforming growth factor-beta1 to human mesenchymal stem cells improves cartilage repair. *Gene Ther*, Vol. 14, No. 10, (May) pp. 804-13, 0969-7128 (Print) 0969-7128 (Linking)
- Pelletier, J. P., Caron, J. P., Evans, C., Robbins, P. D., Georgescu, H. I., Jovanovic, D., Fernandes, J. C.&Martel-Pelletier, J. (1997). In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. *Arthritis Rheum*, Vol. 40, No. 6, (Jun) pp. 1012-9, 0004-3591 (Print) 0004-3591 (Linking)
- Piera-Velazquez, S., Jimenez, S. A.&Stokes, D. (2002). Increased life span of human osteoarthritic chondrocytes by exogenous expression of telomerase. *Arthritis Rheum*, Vol. 46, No. 3, (Mar) pp. 683-93, 0004-3591 (Print) 0004-3591 (Linking)
- Robbins, P. D., Evans, C. H.&Chernajovsky, Y. (2003). Gene therapy for arthritis. *Gene Ther*, Vol. 10, No. 10, (May) pp. 902-11, 0969-7128 (Print) 0969-7128 (Linking)
- Roessler, B. J., Allen, E. D., Wilson, J. M., Hartman, J. W.&Davidson, B. L. (1993). Adenoviral-mediated gene transfer to rabbit synovium in vivo. *J Clin Invest*, Vol. 92, No. 2, (Aug) pp. 1085-92, 0021-9738 (Print) 0021-9738 (Linking)
- Roessler, B. J., Hartman, J. W., Vallance, D. K., Latta, J. M., Janich, S. L.&Davidson, B. L. (1995). Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector. *Hum Gene Ther*, Vol. 6, No. 3, (Mar) pp. 307-16, 1043-0342 (Print) 1043-0342 (Linking)
- Saxer, R. A., Bent, S. J., Brower-Toland, B. D., Mi, Z., Robbins, P. D., Evans, C. H.&Nixon, A. J. (2001). Gene mediated insulin-like growth factor-I delivery to the synovium. *J Orthop Res*, Vol. 19, No. 5, (Sep) pp. 759-67, 0736-0266 (Print) 0736-0266 (Linking)
- Schmal, H., Mehlhorn, A. T., Zwingmann, J., Muller, C. A., Stark, G. B.&Sudkamp, N. P. (2005). Stimulation of chondrocytes in vitro by gene transfer with plasmids coding for epidermal growth factor (hEGF) and basic fibroblast growth factor (bFGF). *Cytotherapy*, Vol. 7, No. 3, pp. 292-300, 1465-3249 (Print) 1465-3249 (Linking)

- Shi, Z. B.&Wang, K. Z. (2010). Effects of recombinant adeno-associated viral vectors on angiopoiesis and osteogenesis in cultured rabbit bone marrow stem cells via co-expressing hVEGF and hBMP genes: a preliminary study in vitro. *Tissue Cell*, Vol. 42, No. 5, (Oct) pp. 314-21, 1532-3072 (Electronic) 0040-8166 (Linking)
- Shuler, F. D., Georgescu, H. I., Niyibizi, C., Studer, R. K., Mi, Z., Johnstone, B., Robbins, R. D.&Evans, C. H. (2000). Increased matrix synthesis following adenoviral transfer of a transforming growth factor beta1 gene into articular chondrocytes. *J Orthop Res*, Vol. 18, No. 4, (Jul) pp. 585-92, 0736-0266 (Print) 0736-0266 (Linking)
- Smith, P., Shuler, F. D., Georgescu, H. I., Ghivizzani, S. C., Johnstone, B., Niyibizi, C., Robbins, P. D.&Evans, C. H. (2000). Genetic enhancement of matrix synthesis by articular chondrocytes: comparison of different growth factor genes in the presence and absence of interleukin-1. *Arthritis Rheum*, Vol. 43, No. 5, (May) pp. 1156-64, 0004-3591 (Print) 0004-3591 (Linking)
- Steinert, A. F., Palmer, G. D., Capito, R., Hofstaetter, J. G., Pilapil, C., Ghivizzani, S. C., Spector, M.&Evans, C. H. (2007). Genetically enhanced engineering of meniscus tissue using ex vivo delivery of transforming growth factor-beta 1 complementary deoxyribonucleic acid. *Tissue Eng*, Vol. 13, No. 9, (Sep) pp. 2227-37, 1076-3279 (Print) 1076-3279 (Linking)
- Steinert, A. F., Proffen, B., Kunz, M., Hendrich, C., Ghivizzani, S. C., Noth, U., Rethwilm, A., Eulert, J.&Evans, C. H. (2009). Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer. *Arthritis Res Ther*, Vol. 11, No. 5, pp. R148, 1478-6362 (Electronic) 1478-6354 (Linking)
- Steinert, A. F., Weber, M., Kunz, M., Palmer, G. D., Noth, U., Evans, C. H.&Murray, M. M. (2008). In situ IGF-1 gene delivery to cells emerging from the injured anterior cruciate ligament. *Biomaterials*, Vol. 29, No. 7, (Mar) pp. 904-16, 0142-9612 (Print) 0142-9612 (Linking)
- Stender, S., Murphy, M., O'Brien, T., Stengaard, C., Ulrich-Vinther, M., Soballe, K.&Barry, F. (2007). Adeno-associated viral vector transduction of human mesenchymal stem cells. *Eur Cell Mater*, Vol. 13, No. pp. 93-9; discussion 99, 1473-2262 (Electronic) 1473-2262 (Linking)
- Surendran, S., Kim, S. H., Jee, B. K., Ahn, S. H., Gopinathan, P.&Han, C. W. (2006). Anti-apoptotic Bcl-2 gene transfection of human articular chondrocytes protects against nitric oxide-induced apoptosis. *J Bone Joint Surg Br*, Vol. 88, No. 12, (Dec) pp. 1660-5, 0301-620X (Print)
- Tang, J. B., Cao, Y., Zhu, B., Xin, K. Q., Wang, X. T.&Liu, P. Y. (2008). Adeno-associated virus-2-mediated bFGF gene transfer to digital flexor tendons significantly increases healing strength. an in vivo study. *J Bone Joint Surg Am*, Vol. 90, No. 5, (May) pp. 1078-89, 1535-1386 (Electronic)
- Tew, S. R., Li, Y., Pothacharoen, P., Tweats, L. M., Hawkins, R. E.&Hardingham, T. E. (2005). Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes. *Osteoarthritis Cartilage*, Vol. 13, No. 1, (Jan) pp. 80-9, 1063-4584 (Print) 1063-4584 (Linking)
- Traister, R. S., Fabre, S., Wang, Z., Xiao, X.&Hirsch, R. (2006). Inflammatory cytokine regulation of transgene expression in human fibroblast-like synoviocytes infected

- with adeno-associated virus. *Arthritis Rheum*, Vol. 54, No. 7, (Jul) pp. 2119-26, 0004-3591 (Print) 0004-3591 (Linking)
- Tsuchiya, H., Kitoh, H., Sugiura, F. & Ishiguro, N. (2003). Chondrogenesis enhanced by overexpression of sox9 gene in mouse bone marrow-derived mesenchymal stem cells. *Biochem Biophys Res Commun*, Vol. 301, No. 2, (Feb 7) pp. 338-43, 0006-291X (Print) 0006-291X (Linking)
- Ulrich-Vinther, M., Maloney, M. D., Goater, J. J., Soballe, K., Goldring, M. B., O'Keefe, R. J. & Schwarz, E. M. (2002). Light-activated gene transduction enhances adeno-associated virus vector-mediated gene expression in human articular chondrocytes. *Arthritis Rheum*, Vol. 46, No. 8, (Aug) pp. 2095-104, 0004-3591 (Print) 0004-3591 (Linking)
- Ulrich-Vinther, M., Stengaard, C., Schwarz, E. M., Goldring, M. B. & Soballe, K. (2005). Adeno-associated vector mediated gene transfer of transforming growth factor-beta1 to normal and osteoarthritic human chondrocytes stimulates cartilage anabolism. *Eur Cell Mater*, Vol. 10, No. (Nov 14) pp. 40-50, 1473-2262 (Electronic) 1473-2262 (Linking)
- Venkatesan, N., Barre, L., Benani, A., Netter, P., Magdalou, J., Fournel-Gigleux, S. & Ouzzine, M. (2004). Stimulation of proteoglycan synthesis by glucuronosyltransferase-I gene delivery: a strategy to promote cartilage repair. *Proc Natl Acad Sci U S A*, Vol. 101, No. 52, (Dec 28) pp. 18087-92, 0027-8424 (Print) 0027-8424 (Linking)
- Wang, X. T., Liu, P. Y., Tang, J. B., Mizukami, H., Xin, K. Q., Ozawa, K. & Ushijima, H. (2007). Tendon healing in vitro: adeno-associated virus-2 effectively transduces intrasynovial tenocytes with persistent expression of the transgene, but other serotypes do not. *Plast Reconstr Surg*, Vol. 119, No. 1, (Jan) pp. 227-34, 1529-4242 (Electronic)
- Wang, X. T., Liu, P. Y., Xin, K. Q. & Tang, J. B. (2005). Tendon healing in vitro: bFGF gene transfer to tenocytes by adeno-associated viral vectors promotes expression of collagen genes. *J Hand Surg Am*, Vol. 30, No. 6, (Nov) pp. 1255-61, 0363-5023 (Print) 0363-5023 (Linking)
- Wehling, P., Reinecke, J., Baltzer, A. W., Granrath, M., Schultiz, K. P., Schultz, C., Krauspe, R., Whiteside, T. W., Elder, E., Ghivizzani, S. C., Robbins, P. D. & Evans, C. H. (2009). Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. *Hum Gene Ther*, Vol. 20, No. 2, (Feb) pp. 97-101, 1557-7422 (Electronic) 1043-0342 (Linking)
- Yokoo, N., Saito, T., Uesugi, M., Kobayashi, N., Xin, K. Q., Okuda, K., Mizukami, H., Ozawa, K. & Koshino, T. (2005). Repair of articular cartilage defect by autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector. *Arthritis Rheum*, Vol. 52, No. 1, (Jan) pp. 164-70, 0004-3591 (Print) 0004-3591 (Linking)
- Yoo, J. U., Mandell, I., Angele, P. & Johnstone, B. (2000). Chondrogenitor cells and gene therapy. *Clin Orthop Relat Res*, Vol. No. 379 Suppl, (Oct) pp. S164-70, 0009-921X (Print) 0009-921X (Linking)
- Zhang, H. G., Xie, J., Yang, P., Wang, Y., Xu, L., Liu, D., Hsu, H. C., Zhou, T., Edwards, C. K., 3rd & Mountz, J. D. (2000). Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. *Hum Gene Ther*, Vol. 11, No. 17, (Nov 20) pp. 2431-42, 1043-0342 (Print) 1043-0342 (Linking)

- Zhang, H. N., Leng, P., Wang, Y. Z. & Zhang, J. (2009). Treating human meniscal fibrochondrocytes with hIGF-1 gene by liposome. *Clin Orthop Relat Res*, Vol. 467, No. 12, (Dec) pp. 3175-82, 1528-1132 (Electronic) 0009-921X (Linking)
- Zhang, X., Mao, Z. & Yu, C. (2004). Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. *J Orthop Res*, Vol. 22, No. 4, (Jul) pp. 742-50, 0736-0266 (Print) 0736-0266 (Linking)
- Zhang, X., Yu, C., Xushi, Zhang, C., Tang, T. & Dai, K. (2006). Direct chitosan-mediated gene delivery to the rabbit knee joints in vitro and in vivo. *Biochem Biophys Res Commun*, Vol. 341, No. 1, (Mar 3) pp. 202-8, 0006-291X (Print) 0006-291X (Linking)

Osteoarthritis - Diagnosis, Treatment and Surgery

Edited by Prof. Qian Chen

ISBN 978-953-51-0168-0

Hard cover, 404 pages

Publisher InTech

Published online 02, March, 2012

Published in print edition March, 2012

Osteoarthritis is one of the most debilitating diseases affecting millions of people worldwide. However, there is no FDA approved disease modifying drug specifically for OA. Surgery remains an effective last resort to restore the function of the joints. As the aging populations increase worldwide, the number of OA patients increases dramatically in recent years and is expected to increase in many years to come. This is a book that summarizes recent advance in OA diagnosis, treatment, and surgery. It includes wide ranging topics from the cutting edge gene therapy to alternative medicine. Such multifaceted approaches are necessary to develop novel and effective therapy to cure OA in the future. In this book, different surgical methods are described to restore the function of the joints. In addition, various treatment options are presented, mainly to reduce the pain and enhance the life quality of the OA patients.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Magali Cucchiarini and Henning Madry (2012). Gene Therapy for Human Osteoarthritis, Osteoarthritis - Diagnosis, Treatment and Surgery, Prof. Qian Chen (Ed.), ISBN: 978-953-51-0168-0, InTech, Available from: <http://www.intechopen.com/books/osteoarthritis-diagnosis-treatment-and-surgery/gene-therapy-for-human-osteoarthritis>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen